Status:
UNKNOWN
Neostigmine Versus Sugammadex on Renal Functions
Lead Sponsor:
Menoufia University
Conditions:
Sugammadex
Neostigmine
Eligibility:
All Genders
20-55 years
Phase:
PHASE4
Brief Summary
The study will assess the acute effects of sugammadex or neostigmine on renal function as determined with more specific and sensitive tests in laparoscopic cholecystectomy
Eligibility Criteria
Inclusion
- normal renal function (serum Cr 0.4- 1.4 g/dL)
- American Society of Anesthesiologists (ASA) Class I-II
Exclusion
- Incapacity to consent.
- Pre-existing impaired kidney functions.
- Severe neuromuscular disease, as: myasthenia gravis \& muscular dystrophy.
- Intra-operative bleeding
- Lengthy operations that exceed 2 hours.
- Hemodynamic changes more than 20% of the base line
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06081738
Start Date
March 1 2023
End Date
December 31 2023
Last Update
October 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Menoufia University Hospitals
Shibīn al Kawm, Menoufia, Egypt, 32513